# CT7439

Source: https://onco.cc/drugs/ct7439/  
OnCo record `ct7439` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

CT7439 is an experimental pill from Carrick Therapeutics, in phase 1 trials for advanced solid tumours.

## Summary

CT7439 is a small molecule, oral from Carrick Therapeutics. Blocks the enzymes CDK12 and CDK13 and acts as a molecular glue that breaks down cyclin K, which the company says weakens the cancer cell's repair of damaged DNA at the level of gene transcription. Its phase 1/2 study (NCT06600789) is recruiting people with solid tumours. CDK13 and cyclin K have no target record in OnCo. Whether it works in people has not been established.

## Fields

- Kind: Treatment
- Status: phase-1
- Last checked: 2026-11-04
- Tags: pipeline; ctgov-ingest
- Code: CT7439
- Modality: Small molecule, oral
- Mechanism: Blocks the enzymes CDK12 and CDK13 and acts as a molecular glue that breaks down cyclin K, which the company says weakens the cancer cell's repair of damaged DNA at the level of gene transcription.

## Sources

- Carrick Therapeutics CDK12/13 programme: https://www.carricktherapeutics.com/pipeline/cdk1213-inhibitor
- ClinicalTrials.gov NCT06600789: https://clinicaltrials.gov/study/NCT06600789

## Connected records

- targets: [CDK12](https://onco.cc/targets/cdk12/)
- companies: [Carrick Therapeutics](https://onco.cc/companies/carrick-therapeutics/)
- trials: [A Modular Phase 1/2 Study With CT7439 in Participants With Solid Malignancies](https://onco.cc/trials/nct06600789/)

---
JSON: https://onco.cc/api/v1/entities/ct7439.json